Anifrolumab Tied to Less Organ Damage for Patients With Lupus

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

THURSDAY, Feb. 20, 2025 -- For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks compared with patients receiving standard of care (SOC), according to a study published online Feb. 7 in the Annals of Rheumatic Disease.

Zahi Touma, M.D., Ph.D., from the University Health Network in Toronto, and colleagues examined whether anifrolumab plus SOC is associated with reduced organ damage accumulation compared with SOC only among adults with moderately to severely active SLE. The anifrolumab arm included patients who initiated 300 mg anifrolumab in the Treatment of Uncontrolled Lupus via the Interferon Pathway trials; real-world (RW) external controls from the University of Toronto Lupus Clinic cohort received SOC only (354 and 561 patients, respectively).

The researchers found that the mean change in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) score was 0.416 points lower in the anifrolumab versus the RW SOC arm after weighting. The likelihood of experiencing an increase in SDI within 208 weeks was lower for patients in the anifrolumab arm (hazard ratio, 0.401).

"In addition to the proven effectiveness of anifrolumab for controlling disease activity, attaining Lupus Low Disease Activity State and remission, and enabling glucocorticoid tapering, this study shows that anifrolumab is effective for preventing long-term organ damage compared to RW SOC," the authors write.

Several authors disclosed ties to pharmaceutical companies, including AstraZeneca, which manufactures anifrolumab and funded the study.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-02-21 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords